NULOJIX (E.R. Squibb & Sons, L.L.C.)
Welcome to the PulseAid listing for the NULOJIX drug offered from E.R. Squibb & Sons, L.L.C.. This T Lymphocyte Costimulation Activity Blockade [PE],Selective T Cell Costimulation Blocker [EPC],CD80-directed Antibody Interactions [MoA],CD86-directed Antibody Interactions [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | E.R. Squibb & Sons, L.L.C. |
| NON-PROPRIETARY NAME: | BELATACEPT |
| SUBSTANCE NAME: | BELATACEPT |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | T Lymphocyte Costimulation Activity Blockade [PE],Selective T Cell Costimulation Blocker [EPC],CD80-directed Antibody Interactions [MoA],CD86-directed Antibody Interactions [MoA] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2011-06-15 |
| END MARKETING DATE: | 0000-00-00 |
NULOJIX HUMAN PRESCRIPTION DRUG Details:
| Item Description | NULOJIX from E.R. Squibb & Sons, L.L.C. |
| LABELER NAME: | E.R. Squibb & Sons, L.L.C. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 250(mg/1) |
| START MARKETING DATE: | 2011-06-15 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0003-0371_8cd30e49-c7bb-4f44-8de9-b0a267d6a3cb |
| PRODUCT NDC: | 0003-0371 |
| APPLICATION NUMBER: | BLA125288 |
Other BELATACEPT Pharmaceutical Manufacturers / Labelers:
